论文部分内容阅读
目的:观察AVASTIN联合泰索帝治疗Her-2阳性乳腺癌的疗效及不良反应;方法:2例Her-2阳性的复发转移性乳腺癌患者均接受AVASTIN联合泰索帝方案治疗,AVASTIN15mg/kg静滴,第1天;同时给予泰索帝75mg/m2,第1天;21天1周期。每周期评价疗效同时记录不良事件。结果:2例患者疗效评价分别为SD(好转)和PR。2例患者均发生白细胞及粒细胞减少4级,脱发、疼痛2级,厌食、腹泻、鼻衄1级,未观察到高血压、静脉血栓、蛋白尿。结论:AVASTIN联合泰索帝可用于治疗Her-2阳性的复发转移性乳腺癌患者,其不良反应能够耐受。
Objective: To observe the curative effect and adverse reactions of AVASTIN combined with taxotere in the treatment of Her-2 positive breast cancer.Methods: Two patients with Her-2 positive recurrent metastatic breast cancer received AVASTIN combined with taxotere regimen and AVASTIN15mg / kg statin Drip on the first day; given Taxotere 75mg / m2, the first day; 21 days a cycle. Evaluation of the efficacy of each cycle while recording adverse events. Results: The efficacy evaluation of two patients were SD (improvement) and PR. Both patients had grade 4 leukopenia and neutropenia, alopecia, grade 2 pain, anorexia, diarrhea and grade 1 rhinitis. No hypertension, venous thrombosis, or proteinuria were observed. Conclusion: AVASTIN combined with taxotere can be used to treat Her-2-positive patients with recurrent metastatic breast cancer and its adverse reactions can be tolerated.